Abstract
Candida albicans biofilms are a complex multilayer community of cells that are resistant to almost all classes of antifungal drugs. The bottommost layers of biofilms experience nutrient limitation where C. albicans cells are required to respire. We previously reported that a protein Ndu1 is essential for Candida mitochondrial respiration; loss of NDU1 causes inability of C. albicans to grow on alternative carbon sources and triggers early biofilm detachment. Here, we screened a repurposed library of FDA approved small molecule inhibitors, to identify those that prevent NDU1-associated functions. We identified an anti-helminthic drug, Niclosamide (NCL), which not only prevented growth on acetate, C. albicans hyphenation and early biofilm growth, but also completely disengaged fully grown biofilms of drug resistant C. albicans and C. auris from their growth surface. To overcome the sub-optimal solubility and permeability of NCL that is well-known to affect its in vivo efficacy, we developed NCL encapsulated Eudragit EPO (an FDA-approved polymer) nanoparticles (NCL-EPO-NPs) with high niclosamide loading, that also provided long-term stability. The developed NCL-EPO-NPs completely penetrated mature biofilms and attained anti-biofilm activity at low microgram concentrations. NCL-EPO-NPs induced ROS activity in C. albicans, and drastically reduced oxygen consumption rate in the fungus, similar to that seen in an NDU1 mutant. NCL-EPO-NPs also significantly abrogated mucocutaneous candidiasis by fluconazole resistant strains of C. albicans, in mice models of oropharyngeal and vulvovaginal candidiasis. To our knowledge, this is the first study that targets biofilm detachment as a target to get rid of drug-resistant Candida biofilms, and uses nanoparticles of an FDA approved non-toxic drug to improve biofilm penetrability and microbial killing.
Introduction
C. albicans is a part of the normal human microbiota. In individuals with compromised immunity, the fungus typically infects target organs by overgrowth or hematogenous spread from colonized sites within the body. The incidence of hematogenously disseminated candidiasis in the United States is ~ 60,000 cases per year, making Candida spp. one of the most-frequently isolated nosocomial bloodstream pathogen1–4, carrying unacceptably high crude and attributable mortality rates of about 40-60%, despite antifungal drug treatment5,6. Of concern is the emergence of intrinsically drug resistant species of Candida, such as C. auris that can be refractory to all classes of FDA-approved antifungal drugs7.
The success of Candida spp. as a pathogen is predominantly due to the organism’s ability to adhere robustly to abiotic surfaces, filament and produce biofilm infections on medical devices8. A biofilm is a community of microbes attached to a surface and encased in an extracellular matrix9–11. Due to the sheer high density of cells12, and the ability of these cells to produce a thick extracellular matrix11,13, cells are shielded from environmental assaults, innate immune cells and from killing by antifungal drugs. Studies of catheter-related Candida infection have unequivocally shown that retention of vascular catheters is linked to prolonged fungemia, failure of antifungal therapy, increased risk of metastatic complications, and death (with mortality rates of >40%)14–16. Unfortunately, in many cases removal of catheters or implanted devices is not possible, therefore alternative strategies to manage biofilms are needed.
Such recalcitrance of biofilm cells is not unique to fungi, but also resonates throughout the bacterial biofilm setting. Antibiotics have often proven impotent against biofilms, and to date no antibiotic has been developed for use against biofilm infections17. The current most-promising focus to combat bacterial biofilms has been to unhinge and disperse them into a population of planktonic cells that would immediately lose properties of antibiotic resistance17–20. Such an approach may not be easy when it comes to Candida biofilms considering fungal biofilms are made up of a scaffold of hyphal elements that cannot be broken easily. However, an approach that could induce early detachment of biofilms might hold promise. Indeed, biofilm dispersed cells are more susceptible to antifungal drugs than parent biofilms21.
Biofilms experience nutrient limitations specifically within the inner layers of the community22. We recently reported that a conserved mitochondrial protein NDU1 is essential for C. albicans respiration and survival in non-fermentative conditions23. Interestingly, C. albicans NDU1 mutant strains could develop biofilms but these biofilms detach early from their growth substrate23. It was determined that the glucose-starved environment within the biofilm lead to increased ROS accumulation and low oxygen consumption rates in NDU1 mutant, culminating to the detachment phenotype. Here, we used NDU1 as a target to screen a repurposed library of FDA-approved small molecule inhibitors (New Prestwick Chemical library) to isolate those that could prevent C. albicans growth in acetate. We identified Niclosamide (NCL), which has a long history of safety and efficacy as an anthelmintic drug in children and adults. When used against Candida, NCL treatment was found to phenocopy the defects of an NDU1 mutant.
NCL is a weakly acidic (pKa: 6.87) hydrophobic drug with very low solubility in water and gastrointestinal fluids, displays poor permeability and intestinal glucuronidation, which sorely limit its oral bioavailability and in vivo efficacy 24. To overcome this drawback, we encapsulated NCL in nanoparticles (NPs) of an FDA-approved cationic polymethylmethacrylate polymer called Eudragit EPO (EPO), to enhance its bioavailability and in vivo efficacy. Here, we elucidate that NCL can stably be encapsulated into EPO NPs with high loading due to the molecular-level interaction between cationic EPO and weakly acidic NCL. NCL loaded EPO NPs (NCL-EPO-NPs) show long-term physicochemical and chemical stability, inhibit growth and filamentation of C. albicans as well as C. auris, prevent biofilm growth (at concentrations as low as 0.5-2 µg/ml), and most importantly, disengage preformed biofilms from their growth material. Furthermore, incorporation of NCL-EPO-NPs into an in-situ thermogelling formulation facilitates their intra-oral delivery and shows significantly potent antifungal activity in two independent mouse models of mucosal infections.
This is the first study targeting the process of biofilm detachment for identification of an anti-biofilm inhibitor. Furthermore, successful repurposing of an FDA-approved inhibitor in a nanoparticulate form for treatment against C. albicans has not been described before. In summary, we have targeted a novel Candida protein (NDU1) using nanoformulation of an FDA-approved antiparasitic drug, facilitating its rapid repurposing and development as an urgently needed antifungal agent.
Results
NCL targets mitochondrial respiration and induces biofilm detachment
Using a forward genetic screening approach, we recently identified and reported on NDU1, a gene controlling C. albicans biofilm dispersal and biofilm detachment23. NDU1 is a mitochondrial inner membrane protein required for respiration via Complex I of the electron transport chain, is essential for growth on alternative carbon sources, and required for virulence in vivo23. Our work highlighted the connection between respiration and biofilm sustenance, where impaired mitochondrial respiratory activity in an NDU1 mutant leads to reduction in biofilm dispersal and early biofilm detachment. As has been well-documented in the bacterial biofilm field17–20, we postulated that targeting early biofilm detachment is a promising approach to combat biofilm-associated infections. To test this hypothesis, we used NDU1 as a target to identify small molecule inhibitors that would inhibit NDU1-associated functions and consequently trigger biofilm detachment.
C. albicans lacking NDU1 are inviable in media containing acetate (or any other non-fermentative carbon sources), but grow as robustly as the wild type (WT) in media with glucose23. We harnessed this unmistakable phenotype to screen a library of 1200 repurposed FDA-approved small molecule inhibitors against a C. albicans strain overexpressing NDU1 (OE) in media containing 1% acetate. An inhibitor that could at a low concentration of 10 µM, curtail biofilm growth of OE in acetate, but not of OE or the WT in glucose was considered a “hit”. This ensured the recognition of an inhibitor that only targets NDU1 and not general viability per se.
A total of 21 inhibitors were identified that prevented >50% of OE in acetate (hit rate of 1.7%; see S1). However, 15 out of the 21 were either disinfectants (e.g. hexachlorophene, thimerosal) or known antifungal drugs (e.g. fluconazole, tioconazole, econazole etc.) that were inhibitory to C. albicans growth even in glucose containing medium (S1) and hence were discarded. We identified antimycin A, a known inhibitor of oxidative phosphorylation as a hit in acetate and not glucose, corroborating our assay that focused on identifying inhibitors of cellular respiration. However, antimycin A is considered extremely toxic and hence disregarded as a molecule of interest. Additional hits were alexidine dihydrochloride and auranofin which we25 and others26 have previously shown to be attractive molecules for antifungal development, and are currently under different stages of drug development. Nevertheless, these drugs inhibited general viability rather than respiration and were rejected for this study. Finally, we identified NCL, an anti-helminthic drug, as the only inhibitor that curtailed biofilm growth of NDU1 OE strain in acetate and not glucose, thereby potentially targeting NDU1 activity, or affecting respiratory chain in a similar manner.
Eudragit EPO (EPO) and NCL show concentration-dependent molecular interaction leading to the stabilization of NCL in the EPO matrix
NCL suffers from major physiochemical drawbacks such as high hydrophobicity, poor permeability and intestinal glucuronidation which leads to poor bioavailability, thereby greatly limiting its widespread clinical applications. Nanoparticles based drug delivery systems have the potential to solubilize hydrophobic drugs like NCL, thus improving permeability and in vivo applicability of the drug27. To identify the nanoformulation polymers suitable for the development of NCL nanoparticles, we first evaluated pharmaceutically accepted anionic (polyvinyl acetate phthalate and Eudragit S100) and cationic (EPO) polymers for their ability to stabilize NCL in the polymer matrix and to facilitate the development of NCL nanoparticles. Our simple solvent-antisolvent precipitation method involving a fixed ratio of NCL and polymers showed that only the EPO-NCL combination could form a stable dispersion. To ascertain the stabilization effect of EPO seen in our screening studies, we evaluated solid-state interaction between NCL and EPO at various ratios (1:10, 2:10, 3:10, and 4:10 w/w) using Fourier-transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy. Our FT-IR spectroscopic studies showed the characteristic peak for –OH and/or N-H (amide) stretching of NCL at 3235 cm−1, while O-H bending and C-N stretching vibrations appeared at ~1340 and 1280 cm−1 respectively (Fig.1A,B). Interestingly, FT-IR spectra of NCL-EPO coevaporates showed disappearance of −OH and/or N-H stretching vibrations of NCL irrespective of the weight ratio (Fig. 1A) whereas O-H bending and C-N stretching vibrations of NCL showed concentration-dependent red shift (Fig. 1B). Additionally, peaks corresponding to dimethylamino group28 (2770 & 2820 cm−1) and the carboxyl group of ester (1723 cm−1) in EPO showed concentration-dependent reduction in the peak intensity along with the red shift in NCL-EPO coevaporates (Fig.1A,B). The changes in FTIR spectra of NCL-EPO coevaporates compared to individual components indicate the strong concentration dependent molecular interaction between NCL and EPO. The spectral changes suggest that hydrogen donating groups in NCL (O-H & N-H) are stabilized by hydrogen accepting groups in EPO (C=O, dimethylamino)29,30 in a concentration-dependent manner31–33.
We further validated the molecular interaction between NCL and EPO using NMR spectroscopy. The NMR spectra of all NCL-EPO coevaporates showed disappearance of the protons corresponding to O-H and N-H functional group in NCL irrespective of the NCL-EPO ratio whereas the protons corresponding to the tertiary amine of EPO (dimethylamino) showed a downfield shift in NCL:EPO ratios 3:10 and 4:10 and decrease in the signal peak intensity at all NCL:EPO ratios, indicating strong hydrogen bond formation between O-H/N-H group of NCL and tertiary amine of EPO 31 (Fig. 1C & D). Additionally, NMR spectra of NCL-EPO coevaporates showed a concentration-dependent downfield shift in the signal of aromatic protons of NCL. It is likely that the cationic center and long polymeric chain of the EPO could influence the electron density of the adjacent methylene units in NCL causing the proton shifts 34. Thus, NMR spectroscopic studies corroborated the inferences from FT-IR studies. Taken together, spectroscopic studies confirmed the ability of EPO to stabilize NCL via molecular level interaction indicating a possibility of developing EPO NPs with a potentially high concentration of NCL.
Eudragit EPO allows for stable encapsulation, high loading, and long-term stability of NCL in nanoparticles
We evaluated various FDA-approved surfactants in a simple and scalable nanoprecipitation method for the development of NCL loaded EPO NPs (NCL-EPO-NPs). Surfactants such as Kolliphor RH 40 (RH 40), Poloxamer 407 (P407), Vitamin E TPGS (TPGS), Kolliphor ELP (ELP), Polysorbate 20 (PS 20): Polysorbate 80 (PS80), Kolliphor HS 15 (HS 15) were evaluated for their ability to yield NCL-EPO-NPs with lowest particle size, acceptable polydispersity index and colloidal stability of at least 1 day (for initial screening). The size, polydispersity, and colloidal stability of NPs varied depending upon the type of surfactant used (Fig 2A). NCL-EPO-NPs stabilized by P407 showed optimal particle size, polydispersity, and colloidal stability and were selected for further development.
Thus, we evaluated the feasibility of developing P407 stabilized EPO-NCL-NPs with higher loading of NCL. It was possible to develop P407 stabilized EPO-NCL-NPs at NCL:EPO ratios of 1:10, 2:10, 3:10, and 4:10 (Fig 2B) indicating the feasibility of developing NCL-EPO-NPs at high NCL loading.
Compared to blank EPO NPs, NCL-EPO-NPs showed lower particle size and surface charge which further confirmed the molecular interaction between NCL and EPO in the nanoparticulate form. The UV spectrophotometric analysis (S2 A,B) showed that the encapsulation efficiency of NCL was > 98% in NCL-EPO-NPs irrespective of the NCL:EPO ratio used for the nanoformulation. NCL-EPO-NPs with NCL loading of 40% (%w/w compared to EPO) showed particle size of 70.2 + 9 nm, the average polydispersity of 0.23, the average zeta potential of +4.5 mV, and excellent colloidal stability (Fig 2 A,B). Any attempts to prepare NCL NPs without EPO immediately led to the precipitation of NCL further confirming the critical role of EPO in the stable encapsulation of NCL (Fig 2C). The TEM imaging showed that EPO-NCL-NPs have spherical morphology (Fig 2D) and their size was in congruence with the size determined by the dynamic light scattering.
We carried out several studies to confirm the molecular interaction between NCL and EPO at the nanoscale. First, we evaluated the fluorescence spectra of NCL solution and NCL-EPO-NPs aqueous dispersion using a spectrofluorometer. The hydroalcoholic NCL solution showed maximum emission at 406 nm, whereas NCL-EPO-NPs dispersed in water showed maximum emission at 526 nm (Fig 3A). The significant red shift and no increase in the fluorescence quantum yield observed in the case of NCL-EPO-NPs indicate strong NCL-EPO interaction and stable encapsulation of NCL at the nanoscale. Further, we freeze dried NCL-EPO-NPs and evaluated the molecular interaction of NCL and EPO in NPs using FT-IR and NMR spectroscopy. As anticipated, the FTIR spectroscopic analysis of freeze dried NCL-EPO-NPs showed the absence of –OH and –NH stretching vibrations of NCL and shifts in the C=O stretching vibration of EPO indicating the retention of molecular interaction between NCL and EPO in the nanoparticles (Fig 3B). Interestingly, a shift in C-O stretch (ether) of P407 (1101 cm−1) was also observed in the freeze dried NCL-EPO-NPs-FD (1090 cm−1) suggesting the molecular interaction between P407 and NCL-EPO which may further help in the stabilization of NCL-EPO NPs (S2C). The changes in the NMR spectrum of freeze-dried NCL-EPO-NPs compared to pure NCL and EPO were similar to that observed in the NCL-EPO coevaporates (described previously), which further confirmed the retention of strong molecular interaction between NCL and EPO in the nanoparticles (Fig 3C; S2D).
It is imperative that the nanoformulation developed after several optimization and characterization experiments maintain long-term physical (size, polydispersity index, surface charge, and pH) and chemical (NCL content) stability. The optimized P407 stabilized NCL-EPO-NPs with different NCL loading (% w/w of EPO) were evaluated for physical and chemical stability for a period of 4 weeks. NCL-EPO-NPs with NCL loading of 40% (% w/w of EPO) showed negligible changes in the particle size, polydispersity, surface charge, and pH over a period of 4 weeks (Fig 4 A,B). The fluorescence spectra of NCL from NCL-EPO-NPs showed no to negligible changes even after 4 weeks (Fig 4C) indicating stable encapsulation and chemical stability of NCL in the nanoparticles. The 4-week stability data for NCL-EPO-NPs with lower NCL loading, and other characteristics are included in the supplementary section (S2E). Thus, we successfully developed P407 stabilized NCL-EPO-NPs with high loading of NCL that have long-term physical and chemical stability.
NCL-EPO-NP display high efficacy against C. albicans and C. auris planktonic as well as biofilm growth
We first validated NCL-EPO-NP in a dose response assay against C. albicans planktonic yeast cells in 96 well plates, growing in media with glucose or with acetate. While NCL-EPO-NP prevented >80% growth of C. albicans in acetate at 1 µg/ml (3 µM), it was not effective against C. albicans viability in glucose (Fig 5A). Viability measured by spot testing (Fig 5B) and XTT assay (Fig 5C) provided a visual and a quantifiable measure of the outcome, respectively. These studies, indicated that NCL-EPO-NP was fungicidal at 0.5-1 µg/ml in acetate, however ineffective in glucose. The effect of the molecule on C. albicans growth in glucose was also pictured by microscopy which clearly revealed a gradual decrease in C. albicans proliferation over dose escalation in acetate, whereas a steady increase in growth in media with glucose (S3A). Importantly, we found that while the nanoparticles had no effect on C. albicans viability in glucose, it potently inhibited C. albicans filamentation at concentrations as low as 0.5 µg/ml (1.5 µM) (Fig 5D). Since NDU1 was used as a target to identify niclosamide, we questioned if C. albicans NDU1 heterozygous strain or its deletion mutant will be more susceptible to NCL-EPO-NP. Certainly, at a concentration as low as 1 µM, both NDU1/ndu1 as well as ndu1/ndu1 exhibited a 29.8% (+1.5%) and 34.5% (+1%) reduction in viability, respectively. This reduction in viability worsened to 63.7% (+4.4%) for the heterozygote and 75.7% (+1.4%) for the homozygote after treatment with 20 µg/ml of NCL-EPO-NP. Remarkably, the drug had no effect on wild type NDU1/NDU1 (0% loss in viability) even at concentrations >80 µg/ml. The NCL-EPO-NP-induced haploinsuffciency of NDU1 suggests that it is required to tolerate and is a target of Niclosamide.
Hyphal growth in C. albicans is vital for tissue invasion. Hence, we tested if the defect in filamentation caused by NCL-EPO-NP could block damage of human umbilical vascular endothelial cells (HUVEC) by C. albicans. Indeed, we found that the NCL-EPO-NPs could prevent 50% damage to HUVEC cells at doses between 2 and 4 µg/ml of NCL. NCL itself did not significantly damage the host cells even at 8 µg/ml (S3B).
Considering that filamentation is also a property imperative for biofilm growth, we investigated the effect of NCL-EPO-NP on C. albicans biofilm formation and on pre-formed biofilms. Again, NCL-EPO-NP prevented C. albicans biofilm growth when added at the time of biofilm initiation in RPMI - a pro-filamentation media that contains glucose. Biofilm growth was interrupted at 1 µg/ml, the dose that limits hyphal growth in the fungus (Fig 6A). In fact, when fully formed biofilms were treated for 24 h with NCL-EPO-NP, the biofilms were found to disintegrate and detach from the wells of the 96 well plate, leading to an overall decrease in biofilm biomass as measured by the XTT assay (Fig 6B, C). Such striking activity of a small molecule against preformed biofilms is uncommon, especially since it does not affect cell viability. Moreover, antifungal drugs have been reported to get sequestered by the biofilm ECM, which nullifies their potency. Thus, we tested the biofilm penetrability of the EPO-NPs stained with coumarin 6 which gave the NP a green color. We found that the nanoparticles could diffuse into the compact biofilm entity (hyphae stained red with Con A) all the way to the bottom of the biofilm cells (Fig 6D, S3C). Overall, our data demonstrate that NCL-EPO-NPs inhibit C. albicans hyphal growth, which has broader implications on virulence in terms of reduced invasion and biofilm growth, resulting in containment of infection and ridding of drug resistant biofilms.
We next questioned if NCL-EPO-NP could also display similar efficacies against drug resistant C. albicans isolates or against the multidrug resistant fungus C. auris. Interestingly, we found that NCL-EPO-NP exhibited inhibitory activity exceeding 80% against two strains of C. auris in media containing glucose or acetate again between low concentrations of 0.5-1 µg/ml (Fig 7A). This meant the molecule was more potent against C. auris than C. albicans in glucose in which it only prevented filamentation. In fact, similar doses also inhibited growth of C. auris biofilms as measured by the XTT assay (Fig 7B) and when visualized by microscopy which showed inhibition of biofilm growth at 1 µg/ml (Fig 7C). Furthermore, the same concentration of NCL-EPO-NP was also efficacious at inhibiting >50% of biofilm growth of two most fluconazole resistant C. albicans strains (fluconazole MIC>128 µg/ml) and C. auris (fluconazole MIC>512) (Fig 7D).
NCL-EPO-NP increase intracellular ROS and reduces oxygen consumption rate in C. albicans
NCL was identified as the drug that potentially targets a mitochondrial protein NDU1 and negatively impacts an important aspect of cellular respiration such as the ability of C. albicans to grow on alternative carbon sources. We further tested its effect on other key features of mitochondrial respiration such as ROS production and mitochondrial oxygen consumption rates. Presence of NCL-EPO-NP significantly increased ROS accumulation in a dose dependent manner, with an 11% increase at 1 µg/ml, 32% increase at 4 µg/ml and 16 µg/ml and ~70% elevation at 64 µg/ml (Fig 7E, S3D). The fact that cells were hypersusceptible to NCL-EPO-NP in acetate indicated a faulty electron transport chain (ETC) activity 23,35. To test this hypothesis, we carried out Seahorse assays to test the respiratory prowess of C. albicans in DMEM medium without glucose, and with NCL. The cells presented a significant decrease in respiratory capacity with increasing doses of the NCL-EPO-NP. The oxygen consumption rate of cells fell below 50% between 0.5-1 µg/ml, and reduced to >90% by 2 µg/ml (Fig 7F, S4A), thus corroborating the findings of NCL MIC in media lacking glucose (Fig 5A-C). Together these results indicate that NCL-EPO-NP target mitochondrial respiration by interfering with the ETC.
NCL-EPO-NP protects mice from mucosal infections
The pronounced in vitro efficacy of NCL-EPO-NP against C. albicans filamentation, invasion and biofilm growth encouraged us to test this molecule in vivo. To facilitate this, we developed a P407-based in-situ gelling formulation containing NCL-EPO-NPs. Following a strategy previously reported by us 36,37, NCL-EPO-NPs were incorporated in an in-situ gelling formulation composed of 20% w/v P407 and 1% w/v Poloxamer 188 (S4B). Incorporation of the NCL-EPO-NP in a gel form allowed us to facilitate their delivery directly into mucosal organs of mice.
We evaluated NCL-EPO-NP first in the established mouse model of oropharyngeal candidiasis (OPC) 38,39. Mice pretreated with corticosteroids were infected sublingually with C. albicans. After allowing the infection to establish for 2 d, cohorts of mice were treated with fluconazole or NCL-EPO-NP gel. Fluconazole was administered systemically, whereas the drug-containing gel was introduced into the mouth of the mice. Antifungal activity was assessed by measuring residual colony forming units (CFU) persisting on the tongue after completing 4 d of therapy. NCL-EPO-NP gel treatment decreased fungal burden by almost one log, compared to untreated mice and mice treated with placebo gel without NCL (Fig 8A). We further investigated the potency of NCL-EPO-NP on OPC infection induced by a fluconazole resistant clinical isolate of C. albicans (fluconazole MIC >128 µg/ml). Again, NCL displayed impressive protection lowering the fungal burden in the oral mucosa by 10 fold versus fluconazole which had no effect on curtailing the infection, as expected (Fig 8B). Microscopic analysis of tongue tissue sections stained by Periodic acid-Schiff (PAS) revealed C. albicans infection of the superficial epithelial layer similar to pseudomembranous OPC in humans38. While placebo gel treated and fluconazole treated mice tongues had widespread infection with abundant tissue penetrating hyphae, NCL treated tongues on the other hand displayed comparatively limited legions, with the infection sites containing a strikingly large numbers of yeasts and pseudohyphae (2X and 10X mag in Fig 8C, 40X mag in S4C). To validate that NCL-EPO-NP is indeed able to repeal mucosal candidiasis, we additionally tested it independently in a mouse model of vulvovaginal candidiasis. Here too we found that NCL-EPO-NP dose of 20 µg almost completely abrogated mice vaginal infections from the fluconazole resistant C. albicans (S4D). Fungal burden in NCL-treated mice was at least 1.5 log lower than placebo or fluconazole treated mice. Overall, these in vivo studies serve as a testimony to the fact that the anti-hyphae/anti-biofilm activity of NCL-EPO-NP seen in vitro is also manifested in vivo thereby proving efficacious in prevention of mucosal candidiasis.
Discussion
Biofilms display physical gradients of nutrients and gases due to metabolic activity and solute diffusion40. The sheer density of cells in an exponentially growing biofilm and the secretion of extrapolymeric substances restrict nutrient diffusion into the innermost layers. This creates a stressful environment especially for the “originator” cells that lay the foundation of biofilm growth on a substrate. Indeed, it is known that C. albicans biofilms provide a hypoxic microenvironment, where oxygen concentration decreases steadily from the top to the bottom layers41. This happens to such a prominent extent, that deeper layers of C. albicans biofilms can sustain growth of obligate anaerobic bacteria. Certainly, the respiratory capacity of C. albicans becomes undeniably necessary during this time, with genes associated with mitochondrial respiration upregulated significantly41. In fact, the respiratory electron transport chain activity also helps C. albicans survive in a glucose-deficient environment, and could prove imperative for adaptation of the fungus to nutrient poor environment in the biofilm core35.
We recently published that NDU1, a C. albicans mitochondrial protein is required for the assembly and activity of the NADH ubiquinone oxidoreductase Complex I (CI) of the respiratory electron transport chain (ETC)23. Absence of NDU1 blocked oxygen uptake, increased ROS accumulation, caused mitochondrial depolarization and prevented C. albicans growth on several alternative carbon sources. This phenotype resulted in hypersusceptibility of the fungus to innate immune cells and rendered Candida avirulent in a disseminated mouse model. Interestingly, while the NDU1 mutant could develop a robust biofilm, these biofilms were fragile and detached easily from their growth substrate23. Although the exact reason of why NDU1 loss causes biofilm detachment is not known, it’s plausible that its absence disallows C. albicans to adapt to the hypoxic and nutrient poor environment rampant in the bottom-most biofilm layers. We utilized these phenotypes to identify inhibitors of NDU1 and inducers of early biofilm detachment.
NDU1 mutant grows as adeptly as the WT in media containing glucose, but is completely inviable in acetate as the sole source of carbon. We created a strain of C. albicans that overexpressed NDU1 (OE), which can grow both on glucose and acetate. From screening a repurposed library of ~1200 FDA approved inhibitors against this strain, we identified NCL which at a low concentration of 10 µM prevented growth of OE in acetate by 50%, but not in glucose. This indicated that NDU1 could be the target of NCL. It also meant that NCL could be a valuable antifungal molecule considering that the host environment is almost devoid of glucose. Host niches, e.g. bloodstream and tissues only have ~0.05 to 0.1% glucose42. FDA approved molecules such as NCL that target respiratory activity of Candida which is needed to survive in vivo, could be a promising new class of antifungals.
NCL is an anthelmintic indicated in the treatment of tapeworm infections in humans. It is listed on the WHO’s list of essential medicines (file:///C:/Users/puppuluri/Downloads/WHO-MVP-EMP-IAU-2019.06-eng.pdf). It has impressive anti-cancer activity (NCI-lead phase I&II clinical trials against prostrate and colon cancer), and has shown remarkable promise for its broad-spectrum antiviral effect, including on SARS-CoV-243–45. Unfortunately, NCL is minimally absorbed from the gastrointestinal tract—neither the drug nor its metabolites have been recovered from the blood or urine46. The poor systemic bioavailability of NCL is because of its limited aqueous solubility of only 0.23 μg/ml. We reckoned that the best use of NCL as an antifungal drug will only be possible if its solubility and absorption characteristics are improved, and the drug can be developed in a way that does not require high doses to enable an antifungal outcome.
One strategy for improving NCM drug solubility has been synthesis of water-soluble analogues47,48. However, these new derivatives require comprehensive preclinical/clinical studies to confirm their efficacy and safety and will face several regulatory hurdles prior to approval. An alternate approach is to transform the formulation of this FDA-approved drug by using into clinically viable nanformulations comprised of pharmacologically acceptable excipients to improve its delivery. We exploited a formulation-based approach using an FDA-approved cationic polymethacrylate polymer Eudragit EPO (EPO), for which the pharmacological and toxicological profiles are already known (https://www.fda.gov/media/107564/download). EPO is used in pharmaceutical products as a coating material to achieve taste masking, moisture protection, modified drug release, and for colon targeting 49–52. Additionally, EPO, in the form of solid dispersion or nanoparticles (NPs), has been used to improve solubility and oral bioavailability of various hydrophobic drugs including weakly acidic drugs53–56.
We and others have previously shown that encapsulation of a weakly acidic and poorly bioavailable anti-inflammatory drug called meloxicam in EPO nanoparticles can improve its efficacy on oral administration with a concomitant reduction in its side effects31,57. Given that NCL is weakly acidic and is as hydrophobic as meloxicam, we hypothesized that cationic EPO could encapsulate and stabilize NCL in the NPs via electrostatic interactions. Our preliminary screening involving anionic carboxylic acid terminated polymers such as Eudragit S100, PVAP and cationic EPO confirmed our hypothesis. Polymeric dispersions prepared with Eudragit S100 or PVAP showed rapid precipitation of NCL indicating insufficient interaction and encapsulation of NCL with the anionic polymers. On the contrary, EPO-NCL dispersion showed significant enhancement in color (yellow color) and no signs of NCL precipitation indicating strong interaction and encapsulation of NCL. Our FT-IR and NMR spectroscopic studies confirmed the strong interaction between NCL and EPO at various ratios and corroborated the color enhancement and higher stability observed for NCL-EPO dispersions. While EPO and NCL dispersion showed signs of stability, in order to develop NPs with long-term stability, we evaluated various FDA-approved nonionic surfactants with different chemical structures and HLB values to prepare NCL-EPO-NPs with lowest size and acceptable homogeneity. While nonionic surfactants such as Kolliphor RH40, Vitamin E TPGS and Kolliphor P407 (P407) yielded NCL-EPO-NPs with similar size, we selected P407 as a stabilizer due to its ability to yield higher stability of NCL-EPO-NPs in the initial screening and its capability to enhance penetration and delivery of nanoparticles to the mucosal surfaces 56,58,59.
The amount of drug loaded into the NPs significantly impacts the total amount of NPs required for the intended therapeutic effect. Our studies on the loading of NCL into NCL-EPO-NPs revealed a possibility of significantly higher NCL loading into NCL-EPO-NPs (NCL: EPO ratio 4:10 or 40% w/w of EPO) without compromising its size and colloidal stability. Interestingly, hitherto reported NCL nanoformulations involving use of materials such as natural polysaccharides (chitosan and xylan), solid lipids, inorganic materials such as mesoporous silica and hallocyte and biodegradable polymers such as polylactide-co-glycolide (PLGA) to load NCL, were unable to achieve NCL loading > 10% and none of these reports evaluated long-term colloidal stability of NCL nanoformulations 60–65. Remarkably, our investigation demonstrated for the first time, high NCL loading in NPs due to strong interaction between NCL and EPO and at least 4-weeks of colloidal stability of NCL-EPO-NP.
The effect of NCL parent drug against Candida has previously been studied in vitro66, against planktonic and biofilm conditions. While that study and ours concur that niclosamide is not fungicidal to C. albicans in media containing glucose, we showed that encapsulation in nanoparticles significantly decreases C. albicans growth and filamentation in glucose containing media (Fig 5A,D; S5A). NCL-EPO-NPs prevented >80% hyphal growth at a striking six to 30 fold lower concentrations than the parent drug alone in RPMI, a hyphal-promoting media (66 and S5B). These low doses of the drug-loaded nanoparticles could also prevent C. albicans invasion of HUVEC cells at a conspicuous 10-15 fold better efficacy than the generic drug alone. Such enhanced anti-invasive activity can be attributed to the complete aqueous solubility, better absorption, and thus improved distribution of NCL due to EPO-nanoparticle encapsulation.
Indeed, prevention of germination and subsequent hyphal formation by NCL-EPO-NPs contributed to its enhanced anti-biofilm activity. Noteworthy was the finding that NCL-EPO-NPs (but not parent NCL; S5C) could disengage developing biofilms early in their development, and penetrate mature biofilms and detach them from their growth surface. Promisingly, NCL-EPO-NPs were not sequestered by the biofilm matrix, a process notoriously known for failure of most antifungal drugs against biofilms67. A previous report suggested that interaction between cationic EPO and anionic fluoroquinolones such as ofloxacin could potentiate the permeation and antibacterial activity of ofloxacin by modulation of the electronegative membrane potential of the bacteria leading to alterations in the outer membrane68. Given the fact that C. albicans exhibits negative membrane potential 69, the enhancement of antifungal activity of NCL via encapsulation into EPO NPs could be a combined effect of nanoencapsulation and modulation of the overall negative membrane potential of the Candida biofilms.
Bottom-most layers of biofilms are hypoxic and nutrient-starved, subjecting the cells present in the deeper layers to stress, which is combatable by upregulating the fungus’s respiratory machinery. Premature detachment of fully formed biofilms due to NCL-EPO-NP treatment could prospectively be due to loss of viability at the bottommost nutritionally disadvantaged layers of the biofilm, coupled with an early loss of adhesion to substrate due to alterations in the cell wall architecture. We have previously elucidated that loss of NDU1 has a direct impact on C. albicans cell wall remodeling and cell membrane integrity (reduction in chitin, cell surface mannan and decrease in ergosterol content) making it susceptible to cell wall and cell membrane perturbing agents23. Biofilm disintegration has been considered the gold standard for ridding bacterial biofilm mediated infections19,70. Truly, prevention of C. albicans biofilms or disintegration of the microbial community early in their development could prove a stellar strategy rendering dissociated cells more susceptible to antifungal drugs21,70. The current study is the first to identify a molecule capable of inducing C. albicans biofilm detachment.
In an alternative carbon source like acetate, NCL-EPO-NPs was found fungicidal. C. albicans can tolerate loss of mitochondrial activity in the presence of glucose, but not in its absence 35. Thus, a drug that targets NDU1, an inner mitochondrial membrane protein necessary for electron transport, is expected to be potent under conditions of stress created by the absence of the preferred carbon source. Indeed, NCL-EPO-NPs displayed many of the same phenotypic/biochemical defects as seen in an NDU1 mutant (ROS accumulation, decrease in OCR). Interestingly, unlike C. albicans, NCL-EPO-NPs killing activity of C. auris was not dependent on carbon source preference. NCL-EPO-NPs prevented planktonic growth of C. auris both in glucose and acetate containing media. C. auris metabolism favors respiration even in the presence of glucose, as evidenced by enrichment in glycolytic and sugar transporter gene expression during yeast growth and TCA cycle protein enrichment compared to C. albicans71,72. Respiratory metabolism enhances ATP production and can reduce oxidative stress, also promoting in vivo fitness and fluconazole resistance73. Thus, NCL-EPO-NP that targets cellular respiration proved lethal to C. auris and is poised to be an attractive novel antifungal drug targeting infections caused by this MDR fungus.
The pronounced in vitro efficacy of NCL-EPO-NPs against C. albicans filamentation, invasion and biofilm growth encouraged us to test this molecule in vivo. Previous characterization of NCL pharmacokinetics have revealed poor absorption, which challenges the drug’s efficacy by reducing the dose that reaches the target tissue, precluding its testing in mouse models of bloodstream Candida infection 74. To overcome this limitation and investigate its antifungal potential in vivo, we tested NCL-EPO-NP in two different mucosal models of candidiasis. For uniform delivery of NCL-EPO-NP on intra-oral and intra-vaginal administration, we incorporated NCL-EPO-NP into our previously reported thermosensitive gel composition containing 20% P407 and 1% Poloxamer 188. We and others have demonstrated that thermosensitive P407 hydrogels can be effectively used for the intra-oral and intra-vaginal application of nanoparticles without affecting their inherent properties and release 36,37,75,76. Additionally, we have previously shown that nanoparticles stabilized with P407 show significant enhancement in mucosal transport in vivo leading to improved efficacy 58,59,77.
Finally, studies have also shown that Poloxamer 407 thermosensitive hydrogel can also interfere with the formation of microbial biofilms 76,78,79. Taken together, usage of mucus-penetrating P407 as a stabilizer for EPO-NCL-NPs and P407 thermosensitive gel to deliver NCL-EPO-NPs was deemed advantageous for improving outcome of in vivo studies. In both OPC 38 as well as the VVC models 80, NCL-EPO-NP significantly prevented mucosal fungal burden. This was unmistakably evident by a reduction in oral thrush on the tongue and oral palette of treated mice. The drug prevented C. albicans filamentation in vivo: histology revealed a remarkable presence of abundant yeast cells in NCL-EPO-NP treated tongue, while the mice treated with placebo or fluconazole displayed a heavy load of filamentous cells. This clearly demonstrated that the efficacy of NCL-EPO-NP in vitro against filamentation and biofilm growth could also be deciphered in vivo in two biofilm models of mucosal candidiasis.
In summary, we have targeted the respiratory function of C. albicans NDU1 to identify an FDA-approved anti-parasitic drug NCL with anti-virulence activity. Additionally, we used an FDA-approved EPO polymer to encapsulate NCL and improve its aqueous solubility, antifungal potency, biofilm penetrability and antifungal activity in vivo. This is the first report on the nanoformulation comprised of FDA-approved components that can detach Candida biofilms in vitro and prevent biofilm infections in vivo. Strategies using FDA-approved molecules and materials can undercut the time required for antifungal development and can enhance antimicrobial activity by improving the physiochemical properties of pharmacologically difficult molecules.
Materials and Methods
Strains, media, and culture conditions
The following fungal strains were used in this study: C. albicans strain SC5314, which is a clinical isolate recovered from a patient with generalized candidiasis 81, and two clinical isolates of Candida spp. received from the Fungus Testing Laboratory at the University of Texas Health Science Center at San Antonio—fluconazole-resistant C. albicans CA6 and CA10. The two C. auris isolates CAU-03 and CAU-09 were a kind gift from Shawn Lockhart, Centers for Disease Control and Prevention (CDC). All cultures were maintained by subculture on yeast-peptone-dextrose medium (YPD) at 37°C, and stocks of these cultures were stored in 20% glycerol at −80°C.
Materials
NCL was purchased from Biosynth-Carbosynth Inc (San Diego, CA). Eudragit® EPO and Eudragit® S100 (Evonik Corporation, Los Angeles, CA), polyvinylacetate phthalate (Colorcon, Inc. West Point, PA), Vitamin E TPGS NF grade (Antares Health Products, Inc., Jonesborough, TN) were received as gift samples. Poloxamer 407 (Kolliphor® P407), Poloxamer 188 (Kolliphor® P188), Kolliphor® ELP, Kolliphor® RH40, Kolliphor® HS15, Kolliphor® PS80, Kolliphor® PS20, were obtained as gift samples from BASF Corporation (Florham Park, NJ). Acetone (AR Grade), scintillation vials (7 ml and 20 ml) and Coumarin C6 were purchased from VWR International (Radnor, PA). Ultra-pure distilled water was used for all experiments.
HTS
Screening was performed at the Molecular Screening Shared Resource facility at the University of California, Los Angeles. A total of 5 × 106 C. albicans yeast cells/ml was suspended in Yeast Nitrogen base containing 2% acetate as an alternative carbon source, and plated (50 µL) into individual 384-well plates using an automated Multidrop 384 system (Thermo Labsystems). The New Prestwick Chemical Library consisting of 1,233 drugs was used to pin one compound per well at 10 µM final concentration, using a Biomek FX liquid handler. Twenty four hours later the plates were scanned with a Flex Station II 384-well plate reader (Molecular Devices) to measure turbidity (OD600) of the wells. Molecules displaying >50% reduction in turbidity compared to control non-drug-treated wells (MIC50) were considered primary “hits.”
Preliminary studies to assess stabilization potential of Eudragit EPO
A preliminary study was carried out to evaluate the potential of Eudragit EPO (cationic polymethacrylate), polyvinylacetate phthalate (PVAP; anionic polycarboxylate), and Eudragit S100 (anionic polymethacrylate) to stabilize weakly acidic NCL. Briefly, NCL (10 mg) and Eudragit EPO/PVAP/Eudragit S100 (100 mg) were transferred to a 20 ml scintillation vial and the mixture was dissolved in 10 ml of acetone to obtain a uniform solution. Ultra-pure water (10 ml) was transferred to a 50 ml clean and dry beaker and the beaker was placed on a magnetic stirrer. Organic solution containing NCL, and the polymer was added dropwise to the aqueous solution and the mixture was stirred at 600 rpm in a fume hood for 3 hours to evaporate acetone. The resultant dispersion was observed for signs of precipitation over a period of time.
Evaluation of concentration-dependent molecular interaction between EPO and NCL using Fourier-transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy
For the spectroscopic studies, NCL and EPO in different weight ratios (% w/w NCL: EPO = 1:10, 2:10, 3:10, and 4:10) were weighed and transferred to a scintillation vial. The mixture was dissolved in acetone to obtain a uniform solution. Acetone was evaporated using a rotary evaporator (Scilogex, LLC, Rocky Hill, CT) to obtain a solid dispersion of NCL and EPO. The solid dispersion was further dried overnight using a vacuum oven (Fisher Scientific, Waltham, MA). The NCL-EPO solid dispersions, EPO, and NCL were evaluated using the FTIR spectrometer (Nicolet iS10, Thermo Scientific, Waltham, MA) equipped with a diamond attenuated total reflection unit. The FTIR spectra were obtained in the transmission mode from 4000 to 500 cm−1. The 1H NMR spectra of NCL-EPO solid dispersions, EPO, and NCL were obtained using a Bruker Avance Digital 400 MHz NMR spectrometer (Bruker, Billerica, MA) coupled to a BACS 1 automatic sample changer. The spectrometer is equipped with a 5-mm PABBO BB-1H/D Z-GRD probe. The spectra of the samples were recorded in (400 μl) deuterated chloroform (CDCl3, Acros Organics, 99.5% D, Waltham, MA) with an average of 16 scans. The chemical shifts were reported in ppm using residual deuterated solvent peaks as an internal reference for 1H NMR: CDCl3 (7.26 ppm).
Development and characterization of NCL loaded Eudragit EPO nanoparticles (NCL-EPO-NPs): Screening of surfactants for their ability to form NCL-EPO-NPs
Various FDA-approved surfactants such as Poloxamer 407 (P407), Kolliphor® ELP (ELP), Kolliphor® RH40 (RH40), Kolliphor® HS15 (HS15), Kolliphor® PS80 (PS80), Kolliphor® PS20 (PS20), and Vitamin E TPGS (TPGS) were screened for the development of NCL-EPO-NPs. Briefly, Eudragit EPO (50 mg), NCL (5 mg), and surfactant (200 mg) were transferred to a 20 mL scintillation vial and the contents were completely dissolved in 10 ml acetone by vortexing (organic phase). The aqueous phase consisting of 10 mL ultra-pure water was transferred to a clean 50 mL beaker. The beaker containing water was placed on a multi-point magnetic stirrer (IKA Works) and the stirrer was set at 600 rpm. The organic phase was slowly added to the aqueous phase to avoid any splashing and to allow the formation of NPs. The stirring was continued for at least 3 hours in a fume hood to allow for complete evaporation of the organic solvent. The nanoparticles synthesis experiment was carried out in triplicate. The size and polydispersity index of various NCL-EPO-NPs were evaluated using Litesizer 500 particle analyzer (Anton-Paar USA, Inc., Torrance, CA). The surfactant that yielded NCL-EPO-NPs with the lowest size and polydispersity index was selected for further experiments.
Preparation of NCL-EPO-NPs with different NCL loading and their characterization
Previously carried out EPO-NCL molecular interaction studies formed the basis for the preparation of NCL-EPO-NPs with different NCL loading. Briefly, NCL (10, 20, 30, or 40 mg), EPO (100 mg), and P407 (400 mg) were transferred to a 20 ml scintillation vial and dissolved in 10 ml of acetone to obtain a homogenous organic phase. The aqueous phase consisting of 10 mL ultra-pure water was transferred to a clean 50 mL beaker. The remaining procedure for the preparation of NCL-EPO-NPs was similar to that described in the earlier section. The size, polydispersity index, and zeta potential of various NCL-EPO-NPs were evaluated using Litesizer 500 particle analyzer (Anton-Paar USA, Inc., Torrance, CA). The nanoparticle synthesis experiment was carried out in triplicate. For TEM imaging, NCL-EPO-NPs with NCL loading of 40% w/w EPO were selected. Briefly, samples were applied to glow-discharged 200 mesh carbon-coated Formvar-coated copper grids and allowed to dry. Grids were viewed on a Hitachi HT7700 TEM at 100kV and photographed with an AMT XR-41B 2k x 2k CCD camera.
Determination of the encapsulation efficiency of NCL in NCL-EPO-NPs
NCL-EPO-NPs dispersion (0.5 ml) was transferred to the Amicon Ultra-0.5 device (3 kDa membrane; Fisher Scientific, Waltham, MA). The Amicon-Ultra centrifugal filter containing NCL-EPO-NPs was centrifuged for 15 min at 14000 rpm (Thermo Scientific, Legend Micro 17R centrifuge). The filtrate was then diluted 10-fold with methanol and NCL concentration in the filtrate was measured at 340 nm using a UV-Vis spectrophotometer. The % encapsulation efficiency (EE) was calculated by the following equation: where ‘Dinitial’ is the amount of NCL/mL of EPO-NCL-NPs dispersion and Dfree is the amount of NCL/mL of the filtrate obtained by the centrifugation of NCL-EPO-NPs.
UV-Vis spectrophotometric determination of NCL from NCL-EPO-NPs
Briefly, NCL (10 mg) and EPO (25 mg) were transferred to a 100 ml volumetric flask and the contents were dissolved in 100 ml methanol to obtain a stock solution of NCL (NCL concentration 100 µg/ml). The stock solution was suitably diluted with methanol:water (99:1) to obtain various NCL concentrations (2, 2.5, 5, 7.5, 10, 15, and 20 µg/ml). The absorbance of solutions containing various NCL concentration was measured at 340 nm using Agilent Carey 60 UV-Vis Spectrophotometer. NCL calibration curve was obtained (n=3) by plotting a graph of NCL absorbance Vs NCL concentration. For the determination of NCL content from NCL-EPO-NPs, the NPs were diluted 100-1000-fold with methanol to obtain NCL concentration with the range established by NCL calibration curve and the absorbance of the NCL was measured at 340 nm.
Evaluation of molecular interaction between NCL and EPO in NCL-EPO-NPs using fluorescence spectroscopy, FT-IR, and 1H-NMR
Fluorescence spectroscopy was used to determine the molecular interaction between EPO and NCL in NCL-EPO-NPs dispersion. Briefly, NCL-EPO-NPs with NCL loading of 40% w/w EPO were diluted with water to obtain a solution with NCL concentration of 25 µg/ml. NCL hydroalcoholic solution (NCL concentration: 25 µg/ml) was used as a control. The fluorescence spectra of NCL from NCL-EPO-NPs dispersion and control NCL solution was evaluated using Shimadzu RF 5301 Spectrofluorometer using an excitation wavelength of 310 nm for NCL solution and 330 nm for NCL-EPO-NPs. For the NCL solution, the excitation wavelength of 310 nm was used to minimize Raman scattering associated with the solvent which interfered with the fluorescence analysis. For FT-IR and NMR characterization, NCL-EPO-NPs were freeze dried. Briefly, NCL-EPO-NPs containing NCL loading of 40% w/w were transferred to a scintillation vial and the contents in the vial were flash frozen using liquid nitrogen. The frozen vial was transferred to a freeze drying flask and the freeze drying flask containing NCL-EPO-NPs samples were loaded on the Labconco FreeZone 12 Plus freeze dryer preset at −80°C temperature and <0.12 mb pressure. After 24 h of lyophilization, the samples were removed from the freeze dryer and the vial containing freeze dried NCL-EPO-NPs were stored in a vacuum desiccator until further use. The freeze dried NCL-EPO-NPs were evaluated using FT-IR and NMR to ascertain molecular interaction between NCL and EPO in the nanoparticles.
Evaluation of long-term physical and chemical stability of EPO-NCL-NPs
The optimized EPO-NCL-NPs containing different loading of NCL were evaluated for the 4-week long physical stability (size, polydispersity index, zeta potential and pH) whereas NCL-EPO-NPs containing 40% w/w NCL was evaluated for 4-weeks long chemical stability using fluorescence spectrophotometer.
Preparation of Coumarin-6 encapsulated polymeric NPs
Briefly, Eudragit EPO (100 mg) and Kolliphor P407 (400 mg) were transferred to a 20 mL scintillation vial along with 9.95 ml of acetone. The contents in the scintillation vial were vigorously vortexed to obtain a clear solution (organic phase). Coumarin-6 (Acros, Organics) was dissolved in acetone at a concentration of 2 mg/mL and added to the organic phase containing polymers to obtain a final concentration of 0.01 mg/mL. The polymeric NPs were prepared as described earlier. The unencapsulated Coumarin-6 in the NPs was removed using Amicon Ultra-0.5 Centrifugal Filter Devices (Amicon Ultra 10K device). Briefly, nanoparticle dispersion (0.5 mL) was transferred to the Amicon-Ultra-0.5 device and centrifuged for 15 min at 14000 rpm (Thermo Scientific, Legend Micro 17R centrifuge). The NPs were washed twice with ultra-pure distilled water to get rid of free Coumarin-6. The filtrate was discarded and the concentrated Coumarin-6 encapsulated polymeric NPs (~100 µL) were collected in a separate tube by inverting and centrifuging the Amicon Ultra filter for 2 min at 1000 rpm. The concentrated NPs were then diluted to their original volume by adding ~400 μL of distilled water, the tube was covered with aluminum foil and stored until further use.
Development of NCL loaded Eudragit EPO nanoparticles (NCL-EPO-NPs) thermosensitive gel
Briefly, 10 mL of blank EPO-NPs were taken in a 20 mL scintillation vial. Kolliphor P407 (20% w/v) and Kolliphor 188 (1% w/v) were added into it and vortexed. The vial was kept in the refrigerator (4° C) for 3 h to ensure total dissolution of surfactants. The same procedure was performed to obtain NCL-EPO-NPs thermosensitive gel of the optimized batch.
Dose-response assays
Dose-response assay of NCL-EPO-NP against planktonically grown fungi was performed in agreement with the CLSI M27-A3 (for yeast) reference standards for antifungal susceptibility testing82. Each drug was used in the concentration range of 0.6 µg/ml to 64 µg/ml, and the MIC of NCL-EPO-NP in media containing 2% acetate was compared to media containing 2% glucose. Inhibition of planktonic growth or filamentation due to drug treatment was also visualized and imaged using bright-field microscopy.
Biofilm growth and drug susceptibility testing
Biofilms of Candida spp. were developed in 96-well microtiter plates, and susceptibility of the biofilm cells to NCL-EPO-NP was determined as described previously 83. Biofilms were initiated in either the presence or absence of the drugs, or the drugs were tested on 48-h preformed biofilms. Inhibition of biofilm growth was measured by a standard colorimetric assay (XTT) that measures metabolic activity of the biofilm cells 83. Absorbance at 490 nm was measured using an automated plate reader. Biofilm disruption by the NCL-EPO-NP were also visualized by bright field microscopy. C. albicans 48 h mature biofilms were also treated with 2 µg/ml coumarin-6 encapsulated NCL-EPO-NP for 24 h. Biofilms were additionally stained with 25 µg/ml concanavalin A to visualize the cells in red. Confocal microscopy with z-stacking feature was performed and images were collected at two wavelengths, 488 nm (GFP) and 594 nm (ConA) as published previously84.
ROS measurement
Intracellular ROS production was detected by staining cells with 5 μM MitoSOX Red (Life Technologies, Frederick, Maryland, USA) in DMSO. Cells from 25-ml cultures grown for 6 h at 30°C in the presence and absence of NCL-EPO-NP in YPD medium were collected and washed twice with PBS. The pellets were suspended to 1 × 106 cells in 1 ml of PBS and treated with or without MitoSOX Red for 45 min at 30°C in the dark. Cell fluorescence in the presence of DMSO alone was used to verify that background fluorescence was similar per strain. Cells from each MitoSOX-treated sample were collected and washed twice with PBS after staining, and mean fluorescence for ROS was quantified.
Oxygen consumption rate assay
OCR were measured under a Seahorse instrument (Seahorse Bioscience, Massachusetts, USA) according to the manufacturer’s instructions. Cells were plated in poly-d-lysine coated XF96 microplates at a density of 5×104 cells/well in 100 µL volume of unsupplemented DMEM (no glucose) with or without NCL-EPO-NP. Samples were run with three technical replicates per condition. The plates were centrifuged at 1000 rpm for 4 minutes without use of the centrifuge break. After centrifugation plate was incubated for 5 minutes before being loaded into a Seahorse XF96 Extracellular Flux Analyzer (Agilent). Basal respiration was measured over six hours with 36 ten-minute protocol cycles including a: 3 minute mix, 4 minute wait, and 3 minute measurement. After six hours, the Complex I and Complex III electron transport chain inhibitors rotenone and antimycin A were injected from Ports A and B at a final concentration of 5µM to determine non-mitochondrial respiration. Data analysis included subtraction of non-mitochondrial respiration from basal respiration measurements before averaging the last 4 basal measurements.
Mammalian cell damage assays
Primary human umbilical vascular endothelial cells (HUVECs) were used to determine the cytotoxicity and efficacy of the NCL-EPO-NP in preventing damage by C. albcians. HUVECs were isolated and propagated by the method of Jaffe et al.85. The cells were grown in M-199 (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum, 10% defined bovine calf serum, and 2 nM l-glutamine, with penicillin and streptomycin. Second- or third-passage endothelial cells were grown on collagen matrix on 96-well microtiter plates. Treatment with NCL-EPO-NP was conducted in M-199 medium. Different concentrations of the nanoparticles were introduced into the cell lines and the wells were also added with 1×105 C. albicans yeast cells. Plates were incubated for 6 h at 37°C in 5% CO2. Damage to HUVEC cells were measured using the chromium release assay well published previously by our group25,86.
Animal models
All animal related study procedures were compliant with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare and were conducted under an IACUC approved protocol 31443-03 by The Lundquist Institute at Harbor-UCLA Medical Center.
Mouse model of oropharyngeal candidiasis (OPC)
Male, 6-week-old CD1 mice were purchased from Taconic. OPC was induced in mice as described previously38. Mice were injected subcutaneously with cortisone acetate (225 mg/kg of body weight) on days −1, 1, and 3 relative to infection. For inoculation, the animals were sedated, and a swab saturated with 2 × 107 C. albicans cells was placed sublingually for 75 min. Mice were either treated intraperitoneally with 10 mg/kg fluconazole on days 3 and 4 after infection. Some mice were treated intra-orally with 200 µg of NCL-EPO-NP on days 1-4. Mice were sacrificed on day 5 after infection. The tongues were harvested, weighed, homogenized for 30 sec, and quantitatively cultured. Some tongues were fixed in zinc-buffered formalin, embedded in paraffin, sectioned, and stained with periodic acid-Schiff (PAS).
Mouse model of vulvovaginal candidiasis
Mice were infected vaginally using a previously well-published protocol80. Five to 6 week old female CD1 mice were injected with 0.1 mL of β-Estradiol 17-valerate in sesame oil, subcutaneously in the back of the neck on day −3 and +3 relative to infection using a needle size of 20G - 27G. For inoculation, the mice were anaesthetized by intraperitoneal (i.p) injection of a mixture of ketamine (82.5 mg/kg) and xylazine (6 mg/kg). Next, 20 μL of PBS containing 5 × 106 C. albicans blastospores was injected into the vaginal lumen. A group of mice were also treated intra-vaginally with fluconazole or NCL-EPO-NP (fluconazole: 10 mg/kg intraperitoneally once on days 3 and 4 after infection; NCL-EPO-NP: 200 µg intra-vaginally on days 1-4). On day 5 post infection, vaginas and ~1 cm of each uterine horn was dissected, homogenized, and quantitatively cultured.
Data availability
The raw data used to reproduce these findings will be shared on request during the review period.
SUPPLEMENTAL 1: Results of the HTS and shortlisting of hits
SUPPLEMENTAL 2: UV-Visible spectra of Niclosamide (NCL-10 ppm), NCL-EPO NPs (equivalent to 10 ppm NCL) & EPO blank NPs (A). Calibration curve for NCL using UV-Vis Spectroscopy (n=3 ± S.D.) (B). Summary of the characteristic FT-IR peaks representing the key functional groups in Eudragit EPO, Niclosamide (NCL), Kolliphor P407 and NCL-EPO-NPs (freeze dried) (C). 1H NMR chemical shifts observed in freeze dried NCL-EPO-NPs in comparison with EPO and NCL (D). Evaluation of particle size, polydispersity index (PDI) and zeta potential of NCL-EPO-NPs containing different loading of NCL (% w/w EPO) on long-term storage at room temperature. (Data expressed as mean ± S.D.; n =3) (E).
SUPPLEMENTAL 3: NCL-EPO-NPs prevent planktonic C. albicans growth in acetate (A), protect HUVEC from damage (B), penetrate C. albicans biofilms (C), and increase ROS activity in the fungus (D)
SUPPLEMENTAL 4: NCL-EPO-NPs reduce oxygen consumption rate in C. albicans a time course analysis (A); NCL-EPO-NPs can be formulated as gel (B); Histology pictures from the OPC model, 40X magnification, scale=20 µm (C); Fungal burden in vagina after drug treatment (D)
SUPPLEMENTAL 5: NCL-EPO-NP reduces C. albicans growth and filamentation at ~0.5 µg/ml in both YP+1% glucose or RPMI medium {when cells remain in the yeast form they fall to the bottom of the round-bottom wells forming a ring that is easily identifiable by the naked eye; filamentation instead displays a fuzzy circumference87}. NCL parent is ineffective even at >32 µg/ml (A,B). Parent NCL or nanoparticle control (NP) did not detach biofilms while NCL-EPO-NP detached preformed biofilms at concentrations as low as 0.5-1 µg/ml (C). NCL-EPO-NP abrogates filamentation at 1 µg/ml, while parent NCL does not, and filaments as efficiently as the no drug control.
Acknowledgements
We would like to thank the following agencies for their financial support to carry out this project: NIH NIAID R01AI141794 awarded to PU and NIH NEI R24EY033598 awarded to AD. The authors would also like to thank BASF Corp, USA, Evonik Industries and Colorcon, Inc. for providing excipients for our research work.
References
- 1.↵
- 2.
- 3.
- 4.↵
- 5.↵
- 6.↵
- 7.↵
- 8.↵
- 9.↵
- 10.
- 11.↵
- 12.↵
- 13.↵
- 14.↵
- 15.
- 16.↵
- 17.↵
- 18.
- 19.↵
- 20.↵
- 21.↵
- 22.↵
- 23.↵
- 24.↵
- 25.↵
- 26.↵
- 27.↵
- 28.↵
- 29.↵
- 30.↵
- 31.↵
- 32.
- 33.↵
- 34.↵
- 35.↵
- 36.↵
- 37.↵
- 38.↵
- 39.↵
- 40.↵
- 41.↵
- 42.↵
- 43.↵
- 44.
- 45.↵
- 46.↵
- 47.↵
- 48.↵
- 49.↵
- 50.
- 51.
- 52.↵
- 53.↵
- 54.
- 55.
- 56.↵
- 57.↵
- 58.↵
- 59.↵
- 60.↵
- 61.
- 62.
- 63.
- 64.
- 65.↵
- 66.↵
- 67.↵
- 68.↵
- 69.↵
- 70.↵
- 71.↵
- 72.↵
- 73.↵
- 74.↵
- 75.↵
- 76.↵
- 77.↵
- 78.↵
- 79.↵
- 80.↵
- 81.↵
- 82.↵
- 83.↵
- 84.↵
- 85.↵
- 86.↵
- 87.↵